Responses
Regular and Young Investigator Award Abstracts
Clinical Trials Completed
578 Feasibility of eftilagimod alpha (soluble LAG-3 protein) combined with standard-of-care-therapy in advanced non-small-cell lung cancer (NSCLC) adenocarcinomas. Initial results from INSIGHT–003
Compose a Response to This Article
Other responses
No responses have been published for this article.